Genfit: leader of SBF 120 after positive data
(CercleFinance.com) - The Genfit share is steaming ahead on the SBF 120 on Monday, up over 9% after a peak of +12% at lunchtime, after the group announced positive data regarding a diagnostic tool.
At the 2017 AASLD Liver Meeting in Boston, on Sunday Genfit presented encouraging results for NIS4, a non-invasive blood tool developed for the diagnosis of non-alcoholic steatohepatitis (NASH).
The French biopharmaceutical company announced that its tool has performed better than other non-invasive tools in the diagnosis of NASH in patients suffering from type 2 diabetes. The program relies on the internal discovery of an algorithm with 4 variables that can potentially replace the biopsy with a single blood test. The study shows that patients with type 2 diabetes have an increased risk of developing NASH.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
At the 2017 AASLD Liver Meeting in Boston, on Sunday Genfit presented encouraging results for NIS4, a non-invasive blood tool developed for the diagnosis of non-alcoholic steatohepatitis (NASH).
The French biopharmaceutical company announced that its tool has performed better than other non-invasive tools in the diagnosis of NASH in patients suffering from type 2 diabetes. The program relies on the internal discovery of an algorithm with 4 variables that can potentially replace the biopsy with a single blood test. The study shows that patients with type 2 diabetes have an increased risk of developing NASH.
Copyright (c) 2019 CercleFinance.com. All rights reserved.